Doximity, Inc. (NYSE:DOCS – Get Free Report)’s stock price fell 8.4% on Wednesday after an insider sold shares in the company. The company traded as low as $24.57 and last traded at $24.2360. 2,318,256 shares traded hands during mid-day trading, a decline of 31% from the average session volume of 3,348,805 shares. The stock had previously closed at $26.45.
Specifically, insider Siddharth Sitaram sold 2,309 shares of the stock in a transaction on Monday, May 11th. The shares were sold at an average price of $25.77, for a total transaction of $59,502.93. Following the completion of the sale, the insider owned 89,396 shares in the company, valued at $2,303,734.92. This represents a 2.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kira Scherer Wampler sold 9,000 shares of the stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $26.06, for a total transaction of $234,540.00. Following the sale, the director owned 19,839 shares of the company’s stock, valued at approximately $517,004.34. This represents a 31.21% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Analysts Set New Price Targets
A number of brokerages recently weighed in on DOCS. Robert W. Baird reiterated a “neutral” rating and set a $18.00 price target (down from $40.00) on shares of Doximity in a research note on Thursday. Jefferies Financial Group cut shares of Doximity from a “buy” rating to a “hold” rating and decreased their price target for the stock from $51.00 to $19.00 in a research note on Thursday. BTIG Research cut shares of Doximity from a “buy” rating to a “neutral” rating in a research note on Thursday. Needham & Company LLC decreased their price target on shares of Doximity from $55.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday. Finally, BMO Capital Markets decreased their price target on shares of Doximity from $25.00 to $20.00 and set a “market perform” rating for the company in a research note on Thursday. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and fourteen have given a Hold rating to the stock. According to MarketBeat, Doximity presently has a consensus rating of “Moderate Buy” and a consensus price target of $30.62.
Key Doximity News
Here are the key news stories impacting Doximity this week:
- Positive Sentiment: Doximity’s fiscal Q4 revenue beat expectations, and management highlighted strong adoption of AI tools and continued customer engagement, suggesting the platform is still growing and gaining traction with clinicians. Doximity Stock Falls on Q4 Earnings Miss, Revenues Beat, Margins Down
- Positive Sentiment: The company announced a partnership with Aledade to bring clinical AI tools into value-based care workflows, reinforcing Doximity’s AI positioning and expanding potential use cases for its products. DOCS Teams Up With Aledade to Bring Clinical AI to Value-Based Care
- Positive Sentiment: Some commentary says the stock may be technically oversold after a steep pullback, with analysts still revising earnings estimates higher, which could support a rebound if sentiment stabilizes. Down 25.7% in 4 Weeks, Here’s Why Doximity (DOCS) Looks Ripe for a Turnaround
- Neutral Sentiment: Analysts and media outlets debated valuation versus Hims & Hers, but this appears more like a relative-value discussion than a direct business catalyst for the stock. DOCS vs. HIMS: Which Stock Is the Better Value Option?
- Negative Sentiment: Doximity reported adjusted EPS of $0.26, missing the broader analyst consensus, which raised concerns that profitability is not meeting expectations. Doximity (DOCS) Lags Q4 Earnings Estimates
- Negative Sentiment: More importantly, FY2027 revenue guidance came in below Wall Street estimates, and the company also signaled higher AI-related spending, which worried investors about slower monetization and margin pressure. Doximity Q4 2026 Earnings Call Transcript
- Negative Sentiment: Several brokerages cut price targets or downgraded the stock, including Baird, Wells Fargo, BMO, Mizuho, Needham, JPMorgan, and Truist, reinforcing the view that near-term expectations have reset lower. Analyst coverage and valuation comparisons
Doximity Trading Up 4.2%
The stock has a market cap of $3.47 billion, a P/E ratio of 18.83, a price-to-earnings-growth ratio of 1.66 and a beta of 1.36. The company has a 50 day simple moving average of $24.09.
Doximity announced that its board has approved a stock buyback program on Thursday, February 5th that permits the company to repurchase $500.00 million in shares. This repurchase authorization permits the company to buy up to 8% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board believes its shares are undervalued.
Institutional Trading of Doximity
Several hedge funds have recently made changes to their positions in DOCS. Carmignac Gestion lifted its stake in shares of Doximity by 355.9% in the 4th quarter. Carmignac Gestion now owns 1,893,026 shares of the company’s stock worth $83,831,000 after acquiring an additional 1,477,798 shares during the period. SG Americas Securities LLC increased its holdings in shares of Doximity by 3,403.2% in the 1st quarter. SG Americas Securities LLC now owns 1,408,597 shares of the company’s stock valued at $32,820,000 after purchasing an additional 1,368,388 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Doximity by 325,436.6% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,298,891 shares of the company’s stock valued at $57,515,000 after purchasing an additional 1,298,492 shares in the last quarter. Federated Hermes Inc. increased its holdings in shares of Doximity by 3,422.7% in the 4th quarter. Federated Hermes Inc. now owns 1,249,085 shares of the company’s stock valued at $55,309,000 after purchasing an additional 1,213,627 shares in the last quarter. Finally, Capital World Investors increased its holdings in shares of Doximity by 25.7% in the 3rd quarter. Capital World Investors now owns 5,381,431 shares of the company’s stock valued at $393,652,000 after purchasing an additional 1,101,848 shares in the last quarter. Institutional investors and hedge funds own 87.19% of the company’s stock.
About Doximity
Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.
The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.
See Also
- Five stocks we like better than Doximity
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.
